Lumenis' Selecta II approved in China
Yokneam, Isr?l-China's regulatory agency for medical devices approved Lumenis to market Selecta II Selective Laser Trabeculoplasty (SLT) technology for treatment of glaucoma. The device reduces IOP associated with glaucoma. The key aspect of Selecta II is that medications are not required postoperatively.
Yokneam, Israel-China's regulatory agency for medical devices approved Lumenis to market Selecta II Selective Laser Trabeculoplasty (SLT) technology for treatment of glaucoma. The device reduces IOP associated with glaucoma. The key aspect of Selecta II is that medications are not required postoperatively.
Patient compliance is an issue in China, since 80% of the visually impaired live in rural areas and 70% of the country's ophthalmologists work in urban hospitals.
"The problem of glaucoma in China is a staggering one," said Ding Lin, MD, PhD, director of Aier Eye Hospital Group, Changsha, China. "In China, as in many other countries, patient compliance to these drops is dismal. We in China welcome SLT as part of the glaucoma management tools."
